secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001737287-24-000072
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene Q3 2024 net loss $66.3M; cash $403.4M; cash runway into 2H 2026
------------------------------------------------------------------------

- Net loss of $66.3M ($0.32/share) including $13.4M stock-based comp and $10.7M impairment; R&D $44.7M, G&A $16.3M.
- Ended Q3 with $403.4M cash; maintains 2024 cash burn ~$200M and runway into 2H 2026.
- Pivotal ALPHA3 cema-cel trial in 1L LBCL: ~30 sites active; enrollment completion expected 1H 2026; BLA submission targeted 2027.
- ALLO-329 (CD19/CD70 dual CAR) for autoimmune disease: IND planned Q1 2025, proof-of-concept by YE 2025.
- ALLO-316 for RCC received RMAT designation; Phase 1 TRAVERSE showed 50% ORR in CD70 TPS ≥50% patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000072/0001737287-24-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000072/allo-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001737287-24-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer